Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Guadecitabine - Astex Pharmaceuticals

Drug Profile

Guadecitabine - Astex Pharmaceuticals

Alternative Names: Decitabine deoxyguanosine; Decitabine deoxyguanosine dinucleotide; DNMT-inhibitor-SGI-110; Guadecitabine-sodium; S-110; SGI-110

Latest Information Update: 09 Jan 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator SuperGen
  • Developer Astex Pharmaceuticals; AstraZeneca; Big Ten Cancer Research Consortium; Columbia University; Fox Chase Cancer Center; Indiana University School of Medicine; John Hopkins University; Memorial Sloan-Kettering Cancer Center; National Cancer Institute (USA); University of Southern California; Weill Cornell Medical College
  • Class Antineoplastics; Aza compounds; Deoxyribonucleosides; Furans; Purine nucleosides; Small molecules; Triazines
  • Mechanism of Action Antimetabolites; DNA cytosine 5 methyltransferase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
  • Phase II Gastrointestinal stromal tumours; Liver cancer; Myeloproliferative disorders; Ovarian cancer; Phaeochromocytoma; Renal cell carcinoma; Solid tumours; T-cell lymphoma; Urogenital cancer
  • Phase I/II Bladder cancer; Colorectal cancer; Renal cancer
  • Phase I Cholangiocarcinoma; Non-small cell lung cancer; Pancreatic cancer; Small cell lung cancer
  • No development reported Germ cell and embryonal neoplasms; Malignant melanoma

Most Recent Events

  • 09 Jan 2019 Efficacy and adverse events data from a phase II trial in Myelodysplastic syndromes presented at 60th Annual Meeting and Exposition of the American Society of Haematology (ASH-Hem-2018)
  • 01 Dec 2018 Efficacy and adverse events data from a phase I/II trial in Myelodysplastic syndromes and Chronic myelomonocytic leukaemia (Combination therapy, Late-stage disease, Second-line therapy or greater) presented at the 60th Annual Meeting and Exposition of the American Society of Haematology (ASH-Hem-2018)
  • 28 Nov 2018 No recent reports of development identified for phase-I development in Malignant-melanoma(Combination therapy, Inoperable/Unresectable, Metastatic disease) in Italy (SC, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top